HomeDenmarkCommit Biologics Raises €5.5M in Seed Financing Extension

Commit Biologics Raises €5.5M in Seed Financing Extension

-

Commit Biologics, an Aarhus, Denmark-based company which specializes in the activation of the complement system to treat cancer and autoimmune disease, raised €5.5M in Seed extension funding.

The round included the contribution from new investor Korys, which brought the total amount to €21.5M.

The company intends to use the funds to further advance the BiCE platform and work towards drug candidate selection, extending its runway into late 2026.

Commit is developing its Bispecific Complement Engaging (BiCE™) platform, which uses single domain antibodies that bind to the complement protein C1q to activate and direct the complement system, a fast-acting and potent part of the innate immune system. BiCE is a modular system that can arm antibodies to direct the complement system in a highly targeted way to selectively kill tumor cells or cells implicated in autoimmune disease.

The company has appointed Chief Scientific Officer Mikkel Wandahl Pedersen as Interim CEO.

FinSMEs

28/01/2025

THE DAILY NEWSLETTER - SIGNUP